Janus Kinase Inhibitors in Dermatology: General Considerations and Applications in Vitiligo and Alopecia Areata

    March 2021 in “ Actas Dermo-Sifiliográficas ”
    Cristina García‐Melendo, Xavier Cubiró, L. Puig
    Studysummary This review discusses the JAK/STAT signaling pathway's role in immune-mediated skin diseases and examines the efficacy and safety of JAK inhibitors for treating vitiligo and alopecia areata, but reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 36

    1. Pro-Inflammatory Vδ1+ T-Cells Infiltrates Are Present In And Around The Hair Bulbs Of Non-Lesional And Lesional Alopecia Areata Hair Follicles Journal of Dermatological Science · 2020
    2. Response of Alopecia Areata of the Beard to Oral Tofacitinib Journal of the American Academy of Dermatology · 2019
    3. A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo Journal of The American Academy of Dermatology · 2019
    4. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    5. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    6. Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2018
    7. Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes JAAD Case Reports · 2018
    8. Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children Journal of the American Academy of Dermatology · 2018
    9. Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study International Journal of Dermatology · 2018
    10. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    11. Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor JAAD case reports · 2018
    12. Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
    13. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    14. Treatment of Vitiligo with the Topical Janus Kinase Inhibitor Ruxolitinib: A 32-Week Open-Label Extension Study with Optional Narrow-Band Ultraviolet B Journal of the American Academy of Dermatology · 2018
    15. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
    16. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    17. Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo Clinical and Experimental Dermatology · 2017
    18. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient Skin appendage disorders · 2017
    19. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    20. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
    21. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    22. Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring International Journal of Dermatology · 2017
    23. Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis Journal of the American Academy of Dermatology · 2017
    24. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    25. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    26. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    27. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    28. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman Acta dermato-venereologica · 2016
    29. Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers Experimental Dermatology · 2016
    30. Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata Journal of the American Academy of Dermatology · 2015
    31. Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
    32. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
    33. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    34. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
    35. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    36. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014